Drugs / RSV 6120/F1/G2/∆NS1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03596801 | Jun 2018 → Apr 2024 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV 6120/F1/G2/∆NS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03596801 ↗ |
| Modality | Vaccine | “recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1)” NCT03596801 ↗ |
| Route | Intranasal | “Delivered as nose drops” NCT03596801 ↗ |